Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Br J Haematol
    April 2024
  1. LIU HC, Huang YJ, Jaing TH, Wu KH, et al
    Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1(plus) and Day 15 MRD positivity.
    Br J Haematol. 2024;204:1344-1353.
    >> Share

  2. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
    Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1367-1374.
    >> Share

  3. CHEN X, Li J, Yu L, Hu W, et al
    High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
    Br J Haematol. 2024;204:1354-1366.
    >> Share

  4. MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al
    Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
    Br J Haematol. 2024;204:1529-1535.
    >> Share

  5. STENTOFT J
    The Mozart effect in chronic myeloid leukaemia.
    Br J Haematol. 2024;204:1139-1140.
    >> Share

  6. PATEL SA
    The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
    Br J Haematol. 2024;204:1137-1138.
    >> Share

  7. ZHANG T, Zhang Y, Zhou M, Zhang Z, et al
    Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:1402-1413.
    >> Share

  8. ALCAZER V, Morisset S, Rea D, Legros L, et al
    Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
    Br J Haematol. 2024;204:1536-1539.
    >> Share

  9. JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al
    Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
    Br J Haematol. 2024;204:1232-1237.
    >> Share

  10. NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al
    Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
    Br J Haematol. 2024;204:1146-1158.
    >> Share

  11. ZUCENKA A, Griskevicius L
    Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:1227-1231.
    >> Share

  12. SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al
    Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1335-1343.
    >> Share

  13. FIEDLER W
    Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
    Br J Haematol. 2024;204:1135-1136.
    >> Share

  14. LIANG P, Xie Y, Liu Z, Wang D, et al
    Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2024;204:1219-1226.
    >> Share

  15. ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al
    Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
    Br J Haematol. 2024;204:1249-1261.
    >> Share

  16. MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al
    Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
    Br J Haematol. 2024;204:1238-1242.
    >> Share

  17. LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al
    Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome.
    Br J Haematol. 2024;204:1288-1292.
    >> Share

    March 2024
  18. LARIBI K, Poulain S, Willems L, Merabet F, et al
    Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19409.
    >> Share

  19. NG HL, Robinson ME, May PC, Innes AJ, et al
    Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
    Br J Haematol. 2024;204:945-958.
    >> Share

  20. SUN H, Zhu Y, Li J, Zhao L, et al
    CSF3R P733T is a deleterious germline variant in acute leukaemia showing gain-of-function-like T618I mutation.
    Br J Haematol. 2024;204:e31-e33.
    >> Share

  21. SHIMONY S, Chen EC
    Tri-ing to decipher trisomy AML.
    Br J Haematol. 2024;204:751-752.
    >> Share

  22. TAN JY, Yeo YH, Tan MC, Chavez JC, et al
    Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
    Br J Haematol. 2024;204:1114-1117.
    >> Share

  23. ZHAO HG
    Should oligomonocytic CMML be classified as an independent disease entity?
    Br J Haematol. 2024;204:749-750.
    >> Share

  24. LAM SSY, Tsui SP, Fung CY, Saw NY, et al
    Distinct karyotypic and mutational landscape in trisomy AML.
    Br J Haematol. 2024;204:939-944.
    >> Share

  25. COPLAND M, Ariti C, Thomas IF, Upton L, et al
    A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
    Br J Haematol. 2024;204:871-876.
    >> Share

  26. CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al
    Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
    Br J Haematol. 2024;204:892-897.
    >> Share

  27. LU Q, Qu W, Wen Y, Ke P, et al
    Single-cell RNA-seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
    Br J Haematol. 2024;204:1100-1104.
    >> Share

  28. RAVANDI F, Dohner H, Wei AH, Montesinos P, et al
    Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
    Br J Haematol. 2024;204:877-886.
    >> Share

  29. MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al
    Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
    Br J Haematol. 2024;204:898-909.
    >> Share

  30. CHEN N, Pan J, Zhou Y, Mao L, et al
    Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:861-870.
    >> Share

    February 2024
  31. COSTA A, Breccia M
    How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
    Br J Haematol. 2024;204:434-448.
    >> Share

  32. PARDANANI A, Reichard K, Tefferi A
    Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Br J Haematol. 2024;204:402-414.
    >> Share

  33. FUJI S, Yuda S, Tada Y, Kano M, et al
    A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL.
    Br J Haematol. 2024;204:e25-e27.
    >> Share

  34. WANG Z, Fan Z, Wu Z, Xuan L, et al
    PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:628-637.
    >> Share

  35. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;204:561-565.
    >> Share

  36. NYQUIST OE, Dalgaard J, Spetalen S, Torkildsen S, et al
    Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML.
    Br J Haematol. 2024;204:724-729.
    >> Share

  37. NARDOZZA AM, Guarnera L, Travaglini S, Ottone T, et al
    Characterization of a novel IDH2-R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation.
    Br J Haematol. 2024;204:719-723.
    >> Share

  38. RAMAMOORTHY S, Lebrecht D, Schanze D, Schanze I, et al
    Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
    Br J Haematol. 2024;204:595-605.
    >> Share

  39. MARK C, Meshinchi S, Joyce B, Gibson B, et al
    Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
    Br J Haematol. 2024;204:576-584.
    >> Share

  40. SHEN Y, Freeman JA, Kerridge I, Downe P, et al
    Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.
    Br J Haematol. 2024;204:487-491.
    >> Share

  41. BAI L, Zhang ZX, Hu GH, Cheng YF, et al
    Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre.
    Br J Haematol. 2024;204:585-594.
    >> Share

    January 2024
  42. MIYASHITA N, Onozawa M, Matsukawa T, Mori A, et al
    Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
    Br J Haematol. 2024 Jan 18. doi: 10.1111/bjh.19292.
    >> Share

  43. NAVRKALOVA V, Plevova K, Radova L, Porc J, et al
    Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naive CLL patients.
    Br J Haematol. 2024;204:240-249.
    >> Share

  44. HASSELBALCH HC, Skov V, Kjaer L, Larsen MK, et al
    Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
    Br J Haematol. 2024;204:16-18.
    >> Share

  45. GJERTSEN BT
    How to discover the exceptional venetoclax responders in AML/MDS?
    Br J Haematol. 2024;204:14-15.
    >> Share

  46. GESTRICH CK, De Lancy SJ, Kresak A, Meyerson H, et al
    IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:229-239.
    >> Share

  47. BARON F, Nagler A, Galimard JE, Sanz J, et al
    Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
    Br J Haematol. 2024;204:250-259.
    >> Share

  48. DE CASTRO FA, Mehdipour P, Chakravarthy A, Ettayebi I, et al
    Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
    Br J Haematol. 2024;204:206-220.
    >> Share

  49. NANAA A, He R, Foran JM, Badar T, et al
    Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
    Br J Haematol. 2024;204:171-176.
    >> Share

  50. MURPHY EL
    HTLV-1 and blood donation.
    Br J Haematol. 2024;204:29-30.
    >> Share

    December 2023
  51. HOKLAND P, Fernandez II, Freeman SD, Gjertsen BT, et al
    AML in the elderly-A global view.
    Br J Haematol. 2023;203:760-773.
    >> Share

  52. WU JF, Abid H, Szabo A, Abid MB, et al
    Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
    Br J Haematol. 2023;203:e117-e120.
    >> Share

  53. HERRITY E, Pereira MP, Kim DDH
    Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions.
    Br J Haematol. 2023;203:722-735.
    >> Share

  54. MAHDI D, O'Nions J, Raj K, Baker R, et al
    Managing molecular relapse of acute myeloid leukaemia in early pregnancy: Is a watch and wait approach reasonable?
    Br J Haematol. 2023;203:e114-e116.
    >> Share

  55. QI P, Wang L, Li H, Wu Y, et al
    Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A single-centre experience.
    Br J Haematol. 2023;203:892-895.
    >> Share

  56. PERUSINI MA, Novitzky-Basso I, Atenafu EG, Forrest D, et al
    Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
    Br J Haematol. 2023;203:781-791.
    >> Share

  57. CHIRIAC R, Humbert C, Mejri A, Debliquis A, et al
    Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia.
    Br J Haematol. 2023;203:699-700.
    >> Share

    November 2023
  58. NG JY, Joshi M, Choi P
    Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
    Br J Haematol. 2023;203:668-672.
    >> Share

  59. BORLENGHI E, Roccaro AM, Cattaneo C
    Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients.
    Br J Haematol. 2023;203:504-506.
    >> Share

  60. REYNOLDS G, Urbancic KF, Fong CY, Trubiano JA, et al
    Invasive fungal infection following venetoclax and posaconazole co-administration.
    Br J Haematol. 2023;203:593-598.
    >> Share

  61. OCADLIKOVA D, Lussana F, Fracchiolla N, Bonifacio M, et al
    Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
    Br J Haematol. 2023;203:637-650.
    >> Share

  62. BOOTH E, Backx M, Joshi A, Nizami H, et al
    Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
    Br J Haematol. 2023;203:499-500.
    >> Share

  63. DONNETTE M, Hamimed M, Ciccolini J, Sicard G, et al
    Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
    Br J Haematol. 2023;203:625-636.
    >> Share

  64. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Li Z, Hammond D, et al
    Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;203:581-592.
    >> Share

  65. APOLITO V, Arrigo G, Vasseur L, Olivi M, et al
    Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.
    Br J Haematol. 2023;203:e98-e101.
    >> Share

    October 2023
  66. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
    The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
    >> Share

  67. PAN X, Chang Y, Ruan G, Wei F, et al
    Prognostic impact of FLT3-ITD mutation on NPM1(+) acute myeloid leukaemia patients and related molecular mechanisms.
    Br J Haematol. 2023;203:212-223.
    >> Share

  68. MAHDI D, Spiers J, Rampotas A, Polverelli N, et al
    Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
    Br J Haematol. 2023;203:169-181.
    >> Share

  69. SEVERIN F, Mouawad N, Ruggeri E, Visentin A, et al
    Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
    Br J Haematol. 2023;203:224-236.
    >> Share

  70. TRAVAGLINI S, Gurnari C, Antonelli S, Marchesi F, et al
    Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept.
    Br J Haematol. 2023;203:327-330.
    >> Share

  71. EADIE LN, Rehn JA, Schutz CE, Heatley SL, et al
    Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling.
    Br J Haematol. 2023;203:282-287.
    >> Share

    September 2023
  72. RHODES J
    FISH-ing for answers: Can genomic arrays add to our understanding of disease biology in low-risk chronic lymphocytic leukaemia?
    Br J Haematol. 2023;202:922-924.
    >> Share

  73. RADICH JP
    The (near) miracle of therapy in chronic myeloid leukaemia.
    Br J Haematol. 2023;202:919-921.
    >> Share

  74. PATNANA PK, Liu L, Frank D, Nimmagadda SC, et al
    Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells.
    Br J Haematol. 2023;202:1033-1048.
    >> Share

  75. HUA L, Yang N, Li Y, Huang K, et al
    Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway.
    Br J Haematol. 2023;202:971-984.
    >> Share

  76. LI H, Yuan L, Wang P, Sheng Y, et al
    Clonal architecture and single-cell transcriptome landscape in Richter's syndrome.
    Br J Haematol. 2023;202:1055-1060.
    >> Share

  77. RIGOLIN GM, Traversa A, Caputo V, Del Giudice I, et al
    Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients.
    Br J Haematol. 2023;202:953-959.
    >> Share

  78. DE JOHN KO, De Quintal H, Mathibe MD, Albertus N, et al
    A rare case of acute megakaryoblastic leukaemia with constitutional ring chromosome 21.
    Br J Haematol. 2023;202:912.
    >> Share

  79. SHAH NP, Garcia-Gutierrez V, Jimenez-Velasco A, Larson SM, et al
    Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
    Br J Haematol. 2023;202:942-952.
    >> Share

  80. BRECCIA M, Saglio G
    Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
    Br J Haematol. 2023;202:1087-1088.
    >> Share

  81. HADDAD FG, Kourie HR, Saleh K
    Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:1084-1086.
    >> Share

  82. IRANI YD, Hughes A, Kok CH, Clarson J, et al
    Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
    Br J Haematol. 2023;202:1127-1136.
    >> Share

  83. FENG H, Fu Y, Cui Z, Zhou M, et al
    Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
    Br J Haematol. 2023;202:1178-1191.
    >> Share

  84. PESCHKE JC, Bergmann R, Mehnert M, Gonzalez Soto KE, et al
    FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
    Br J Haematol. 2023;202:1137-1150.
    >> Share

  85. PASTORE F, Gittinger H, Raab S, Tschuri S, et al
    Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
    Br J Haematol. 2023;202:1165-1177.
    >> Share

  86. XIE M, Lu Y, Ouyang G, Li X, et al
    Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
    Br J Haematol. 2023;202:1119-1126.
    >> Share

  87. MATSUMOTO K, Kakazu N, Imataki O, Kondo A, et al
    Hairy cell leukaemia with an IGH-BRAF fusion gene.
    Br J Haematol. 2023;202:e67-e70.
    >> Share

  88. BELHADJ M, Burroni B, Kosmider O, Willems L, et al
    Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
    Br J Haematol. 2023;202:e50-e53.
    >> Share

    August 2023
  89. LAHERA A, Vela-Martin L, Lopez-Nieva P, Salgado RN, et al
    Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL.
    Br J Haematol. 2023;202:693-698.
    >> Share

  90. GE SS, Qiu QC, Dai HP, Shen XD, et al
    Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy.
    Br J Haematol. 2023;202:539-549.
    >> Share

  91. MA Z, Ye W, Wang J, Huang X, et al
    Glutamate dehydrogenase 1: A novel metabolic target in inhibiting acute myeloid leukaemia progression.
    Br J Haematol. 2023;202:566-577.
    >> Share

  92. ZHOU L, Fu W, Wu S, Xu K, et al
    Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study.
    Br J Haematol. 2023;202:517-524.
    >> Share

  93. NI SC, Lin CC
    Pseudothrombocytosis in Acute Myeloid Leukaemia.
    Br J Haematol. 2023;202:456.
    >> Share

  94. MILADINOVIC M, Klusmann JH
    Influenza A (H1N1) virus induced long-term remission in a refractory acute myeloid leukaemia.
    Br J Haematol. 2023;202:713-714.
    >> Share

  95. HUO WX, Wen Q, Zhang XH, Xu LP, et al
    Outcomes of haploidentical haematopoietic stem cell transplantation for adolescent and young adults with acute myeloid leukaemia.
    Br J Haematol. 2023;202:856-865.
    >> Share

  96. NG LIET HING M, Ryland GL, Nguyen T, Tiong IS, et al
    Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
    Br J Haematol. 2023;202:893-896.
    >> Share

  97. YOU L, Liu Y, Chen N, Zhu L, et al
    Influenza A (H1N1) virus induced long-term remission in a refractory acute myeloid leukaemia.
    Br J Haematol. 2023;202:745-748.
    >> Share

  98. RIVA G, Luppi M, Tagliafico E
    From gating to computational flow cytometry: Exploiting artificial intelligence for MRD diagnostics.
    Br J Haematol. 2023;202:715-717.
    >> Share

  99. NGUYEN PC, Nguyen V, Baldwin K, Kankanige Y, et al
    Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.
    Br J Haematol. 2023;202:760-770.
    >> Share

  100. KUSUDA M, Nakasone H, Yoshimura K, Okada Y, et al
    Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted CTLs specific to HTLV-1 in ATL patients.
    Br J Haematol. 2023;202:578-588.
    >> Share

  101. LOKE J, Upasani V, Gaskell C, Fox S, et al
    Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
    Br J Haematol. 2023;202:498-503.
    >> Share

  102. SARTOR C, Brunetti L, Audisio E, Cignetti A, et al
    A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
    Br J Haematol. 2023;202:599-607.
    >> Share

  103. BORRILL R, Poulton K, Kusyk L, Routledge A, et al
    Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8(+) T-cell expansion, significant cytokine release syndrome and induction of disease remission.
    Br J Haematol. 2023;202:589-598.
    >> Share

    July 2023
  104. KASSEM AM, Keinath MC, Adler JA, Gadde R, et al
    ZBTB16::RARA variant acute promyelocytic leukemia (vAPL) treated with gemtuzumab ozogamicin (GO) with unique pathology and genetic findings.
    Br J Haematol. 2023 Jul 26. doi: 10.1111/bjh.18950.
    >> Share

  105. FALINI B, Cardinali V, Brunetti L, Martelli MP, et al
    NPM1-mutated AML with starry sky pattern.
    Br J Haematol. 2023;202:8.
    >> Share

  106. HUO L, Zhang Z, Zhou H, Xie J, et al
    Causative germline variant p.Y259C of DDX41 recurrently identified in acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:199-203.
    >> Share

  107. DOAN A, Huang HKT, Hadar AJ, Malvar J, et al
    Efficacy and safety of FLAG-IDA as front-line therapy in de novo paediatric acute myeloid leukaemia population.
    Br J Haematol. 2023;202:e3-e6.
    >> Share

  108. ZHU X, Jiang Q, Lu J, Sun Y, et al
    COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.
    Br J Haematol. 2023;202:31-39.
    >> Share

  109. ZHANG X, Wang Z, Sun J, Liu L, et al
    New insights into the clinical characteristics of SETD2-mutated acute myeloid leukaemia.
    Br J Haematol. 2023;202:111-115.
    >> Share

  110. ERKELAND SJ
    Computational analysis of a microRNA signature for poor prognosis suggests a microRNA-controlled stemness pathway in paediatric acute leukaemia.
    Br J Haematol. 2023;202:11-12.
    >> Share

  111. FIGUEROA-MORA R, Rampotas A, Halperin D, Worth T, et al
    Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.
    Br J Haematol. 2023;202:48-53.
    >> Share

  112. ESPERANZA-CEBOLLADA E, Gomez-Gonzalez S, Perez-Jaume S, Vega-Garcia N, et al
    A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia.
    Br J Haematol. 2023;202:96-110.
    >> Share

  113. JO T, Arai Y, Oshima S, Kondo T, et al
    Prognostic impact of complex and/or monosomal karyotypes in post-transplant poor cytogenetic acute myeloid leukaemia: A quantitative approach.
    Br J Haematol. 2023;202:356-368.
    >> Share

  114. SYSTCHENKO T, Chomel JC, Gallego-Hernanz P, Moya N, et al
    Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
    Br J Haematol. 2023;202:284-288.
    >> Share

  115. STRULLU M, Fenneteau O, Lainey E
    Cannibalism in an ETV6::RUNX1 paediatric B acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:211.
    >> Share

  116. LI T, Zhang Y, Wang K, Zhou H, et al
    Leukaemic blasts in a urine specimen in acute myeloid leukaemia with CEBPA mutation.
    Br J Haematol. 2023;202:212.
    >> Share

  117. LV M, Liu L, He Y, Yang D, et al
    Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease.
    Br J Haematol. 2023;202:369-378.
    >> Share

  118. OFVERHOLM I, Rezayee F, Heyman M, Harila A, et al
    The prognostic impact of IKZF1 deletions and UKALL genetic classifiers in paediatric B-cell precursor acute lymphoblastic leukaemia treated according to NOPHO 2008 protocols.
    Br J Haematol. 2023;202:384-392.
    >> Share

  119. WANG W, Li X, Qin X, Miao Y, et al
    Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
    Br J Haematol. 2023;202:328-343.
    >> Share

  120. GURNEY M, Chekkaf I, Baranwal A, Basmaci R, et al
    The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
    Br J Haematol. 2023;202:279-283.
    >> Share

    June 2023
  121. MUNTANOLA A, Villalobos MT, Gonzalez-Villambrosia S, Rodriguez-Salazar MJ, et al
    Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
    Br J Haematol. 2023 Jun 30. doi: 10.1111/bjh.18912.
    >> Share

  122. TURNER R, Quach H, Horvath N, Kerridge I, et al
    Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
    Br J Haematol. 2023 Jun 18. doi: 10.1111/bjh.18914.
    >> Share

  123. LIU Y, Zhu L, Lv Z, Mao L, et al
    Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
    Br J Haematol. 2023;201:995-999.
    >> Share

  124. XIE X, Zhang W, Zhou X, Ye Z, et al
    Abemaciclib drives the therapeutic differentiation of acute myeloid leukaemia stem cells.
    Br J Haematol. 2023;201:940-953.
    >> Share

  125. VAINER N, Aarup K, Andersen MA, Wind-Hansen L, et al
    Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2023;201:874-886.
    >> Share

  126. RIEU JB, Canali A, Thene E, Tavitian S, et al
    Acute promyelocytic leukaemia associated with atypical basophilia.
    Br J Haematol. 2023;201:1017.
    >> Share

  127. YOKOYAMA S, Onozawa M, Yoshida S, Miyashita N, et al
    Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis.
    Br J Haematol. 2023;201:1144-1152.
    >> Share

  128. SIMOES C, Villar S, Ariceta B, Garces JJ, et al
    Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
    Br J Haematol. 2023;201:1239-1244.
    >> Share

  129. BRONSTEIN Y, Levi S, Herishanu Y
    Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.
    Br J Haematol. 2023;201:1125-1128.
    >> Share

  130. DULUCQ S, Rigal-Huguet F, Nicolini FE, Cony-Makhoul P, et al
    Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
    Br J Haematol. 2023;201:1116-1124.
    >> Share

  131. MENEZES DL, See WL, Risueno A, Tsai KT, et al
    Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
    Br J Haematol. 2023;201:1129-1143.
    >> Share

  132. NAGLER A, Labopin M, Dholaria B, Blaise D, et al
    Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
    Br J Haematol. 2023;201:1169-1178.
    >> Share

  133. ISHIDA H, Imamura T, Tatebe Y, Ishihara T, et al
    Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL-02 protocol.
    Br J Haematol. 2023;201:1200-1208.
    >> Share

    May 2023
  134. PUCKRIN R, Owen C, Stewart D, Peters A, et al
    Real-world management of small lymphocytic lymphoma as chronic lymphocytic leukaemia versus an indolent non-Hodgkin lymphoma.
    Br J Haematol. 2023 May 25. doi: 10.1111/bjh.18879.
    >> Share

  135. SAVOY L, Long N, Lee H, Chen R, et al
    CDK12/13 dual inhibitors are potential therapeutics for acute myeloid leukemia.
    Br J Haematol. 2023 May 14. doi: 10.1111/bjh.18843.
    >> Share

  136. JEDIDI I, Krichen I, Chaari M, Louati N, et al
    Auer-rod like inclusions in mature neutrophils of an early T cell precursor lymphoblastic leukaemia patient after SARS-CoV-2 infection.
    Br J Haematol. 2023;201:378.
    >> Share

  137. LUNDIN-STROM KB, Biloglav A, Castor A, Olsson-Arvidsson L, et al
    Acquired uniparental isodisomies involving chromosome 12 in paediatric B-cell precursor acute lymphoblastic leukaemia: Associations with chromosome 21 gains and SH2B3 mutations.
    Br J Haematol. 2023;201:585-588.
    >> Share

  138. WANG H, Yao Y, Mao L, Lou Y, et al
    Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.
    Br J Haematol. 2023;201:568-572.
    >> Share

  139. MAURO FR, Visentin A, Giannarelli D, Molinari MC, et al
    Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents.
    Br J Haematol. 2023;201:564-567.
    >> Share

  140. JING CB, Prutsch N, He S, Zimmerman MW, et al
    Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.
    Br J Haematol. 2023;201:489-501.
    >> Share

  141. CARRILLO-TORNEL S, Chen-Liang TH, Zurdo M, Puiggros A, et al
    NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition.
    Br J Haematol. 2023;201:470-479.
    >> Share

  142. TIACCI E, Mancini A, Marchetti M, D'Elia GM, et al
    SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia.
    Br J Haematol. 2023;201:411-416.
    >> Share

  143. JONART LM, Ostergaard J, Brooks A, Fitzpatrick G, et al
    CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
    Br J Haematol. 2023;201:459-469.
    >> Share

  144. POPOV A, Tsaur G, Verzhbitskaya T, Riger T, et al
    Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements.
    Br J Haematol. 2023;201:510-519.
    >> Share

  145. COLLIGNON C, Domenech C, Ducassou S, Pluchart C, et al
    Temporary contraindication to chemotherapy due to toxicity: blinatumomab's effectiveness in paediatric patients with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2023;201:e42-e45.
    >> Share

  146. CHEN R, Atenafu EG, Seki J, Liu X, et al
    Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2023;201:645-652.
    >> Share

  147. LAHERA A, Lopez-Nieva P, Alarcon H, Marin-Rubio JL, et al
    SOCS3 deregulation contributes to aberrant activation of the JAK/STAT pathway in precursor T-cell neoplasms.
    Br J Haematol. 2023;201:718-724.
    >> Share

  148. HAMA A, Taga T, Tomizawa D, Muramatsu H, et al
    Haematopoietic cell transplantation for children with acute megakaryoblastic leukaemia without Down syndrome.
    Br J Haematol. 2023;201:747-756.
    >> Share

  149. KARLSSON L, Cheuk D, De Moerloose B, Hasle H, et al
    Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia.
    Br J Haematol. 2023;201:757-765.
    >> Share

    April 2023
  150. CASTAGNA L, Patti K, Mule A
    Don't forget cord blood in non-remission acute myeloid leukaemia!
    Br J Haematol. 2023;201:11-12.
    >> Share

  151. ZHENG Y, Weng X, Hu D, He J, et al
    Identification of a signature based on non-apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia.
    Br J Haematol. 2023;201:95-105.
    >> Share

  152. SORCINI D, De Falco F, Gargaro M, Bozza S, et al
    Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2023;201:45-57.
    >> Share

  153. MATSUDA K, Konuma T, Fuse K, Masuko M, et al
    Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: A nationwide retrospective study.
    Br J Haematol. 2023;201:106-113.
    >> Share

  154. DEL GIUDICE I, Cappelli LV, Delgado J, Niemann CU, et al
    Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.
    Br J Haematol. 2023;201:353-356.
    >> Share

  155. WANG YH, Yao CY, Lin CC, Gurashi K, et al
    A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;201:302-307.
    >> Share

  156. MA H, Wang S, O'Brien S, Kern M, et al
    How we approach the perioperative management of patients with chronic lymphocytic leukaemia receiving continuous cancer-directed therapies.
    Br J Haematol. 2023;201:215-221.
    >> Share

  157. SALOMAO N, Maslah N, Giulianelli A, Drevon L, et al
    Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia.
    Br J Haematol. 2023;201:234-248.
    >> Share

  158. SINGH C, Yanamandra U, Karunakaran P, Jindal N, et al
    Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
    Br J Haematol. 2023;201:249-255.
    >> Share

    March 2023
  159. SPACEK M, Smolej L, Simkovic M, Nekvindova L, et al
    Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR).
    Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18736.
    >> Share

  160. SHEN K, Yang C
    Occult optic nerve neurolymphomatosis of T-lymphoblastic lymphoma detected by PET/MRI.
    Br J Haematol. 2023 Mar 27. doi: 10.1111/bjh.18725.
    >> Share

  161. ROUZAUD C, Vercellino L, De Kerviler E, Raffoux E, et al
    Prognostic value of PET/CT and CT in T-cell lymphoblastic lymphoma/leukaemia patients: A retrospective cohort study of 145 patients.
    Br J Haematol. 2023 Mar 8. doi: 10.1111/bjh.18707.
    >> Share

  162. EL HUSSEIN S, Wang W
    Plasmacytoid dendritic cells in the setting of myeloid neoplasms: Diagnostic guide to challenging pathologic presentations.
    Br J Haematol. 2023;200:545-555.
    >> Share

  163. FRISCH A, Rowe JM, Ofran Y
    The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia.
    Br J Haematol. 2023;200:556-562.
    >> Share

  164. MATSUDA K, Konuma T, Yanada M
    Cord blood versus haploidentical transplantations for non-remission acute myeloid leukaemia: Authors' reply.
    Br J Haematol. 2023;200:678-679.
    >> Share

  165. SCARADAVOU A, Boelens JJ
    Lower probability of relapse after myeloablative cord blood transplantation for patients with refractory AML.
    Br J Haematol. 2023;200:676-677.
    >> Share

  166. MUSSAI F, De Santo C, Cheng P, Thomas IF, et al
    A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.
    Br J Haematol. 2023;200:573-578.
    >> Share

  167. CHOI Y, Choi EJ, Park HS, Lee JH, et al
    A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors-A single-centre, prospective, explorative study.
    Br J Haematol. 2023;200:608-621.
    >> Share

  168. AGUILAR NAVARRO AG, Tikhonova AN
    Treatment response in acute myeloid leukaemia-Clues in the biopsy core.
    Br J Haematol. 2023;200:691-693.
    >> Share

  169. TREABA DO, Bonal DM, Chorzalska A, Castillo-Martin M, et al
    Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles.
    Br J Haematol. 2023;200:740-754.
    >> Share

    February 2023
  170. MESZAROS N, Lind K, Sehlke R, Vilagos B, et al
    Influence of cryopreservation on drug responses and gene expression of AML cells: Implications for the use of biobanked tissues.
    Br J Haematol. 2023;200:e32-e36.
    >> Share

  171. MANGUM DS, Bishop JD, Zhou Y, Cheng C, et al
    Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis.
    Br J Haematol. 2023;200:338-343.
    >> Share

  172. CHATTERJEE G, Patkar N
    United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward.
    Br J Haematol. 2023;200:277-279.
    >> Share

  173. BARNES EJ, Eide CA, Kaempf A, Bottomly D, et al
    Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.
    Br J Haematol. 2023;200:323-328.
    >> Share

  174. IKOMA-COLTURATO MRV, Bertolucci CM, Conti-Spilari JE, Oliveira E, et al
    Multicentric standardization of minimal/measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low/middle-level income country.
    Br J Haematol. 2023;200:381-384.
    >> Share

  175. KULIS M, Martin-Subero JI
    Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications.
    Br J Haematol. 2023;200:280-290.
    >> Share

  176. GOURSAUD L, Berthon C, Quesnel B
    Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG-asparaginase.
    Br J Haematol. 2023;200:e37-e39.
    >> Share

  177. RAKOTOARIVELO ZH, Lefebvre T, Lamarque M, Harzallah I, et al
    Bundles of Auer rods in mature neutrophils in an acute myeloid leukaemia patient with inv(16)(p13.1q22) CBFB-MYH 11.
    Br J Haematol. 2023;200:398.
    >> Share

  178. TIAN C, Chen Z, Wang L, Si J, et al
    Over expression of ubiquitin-conjugating enzyme E2O in bone marrow mesenchymal stromal cells partially attenuates acute myeloid leukaemia progression.
    Br J Haematol. 2023;200:476-488.
    >> Share

  179. HUANG T, Xu L, Zhang X, Chang Y, et al
    Haploidentical haematopoietic stem cell transplantation for TP53-mutated acute myeloid leukaemia.
    Br J Haematol. 2023;200:494-505.
    >> Share

  180. MADRY K, Lis K, Fenaux P, Bowen D, et al
    Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
    Br J Haematol. 2023;200:451-461.
    >> Share

  181. DARGENIO M, Bonifacio M, Chiaretti S, Vitale A, et al
    Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
    Br J Haematol. 2023;200:440-450.
    >> Share

  182. GJAERDE LK, Jakobsen LH, Juhl-Christensen C, Olesen G, et al
    Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population-based cohort study.
    Br J Haematol. 2023;200:e40-e43.
    >> Share

    January 2023
  183. WILSON J
    Pseudo-faggot cells in splenic marginal zone lymphoma.
    Br J Haematol. 2023 Jan 6. doi: 10.1111/bjh.18621.
    >> Share

  184. OLOFSEN PA, Bosch DA, de Looper HWJ, van Strien PMH, et al
    Truncated CSF3 receptors induce pro-inflammatory responses in severe congenital neutropenia.
    Br J Haematol. 2023;200:79-86.
    >> Share

  185. ZHANG T, Liu X, Fei H, Zhang L, et al
    Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;200:256-260.
    >> Share

  186. PAUL SR, Rosing DR, Haigney MC, Peer CJ, et al
    Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia.
    Br J Haematol. 2023;200:261-263.
    >> Share

  187. WIERNIK PH
    Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
    Br J Haematol. 2023;200:126-127.
    >> Share

  188. GURNARI C, Pagliuca S
    Digging into the HLA pockets: A new association with acute leukaemias.
    Br J Haematol. 2023;200:123-125.
    >> Share

  189. MEHTA P, Telford N, Wragg C, Dillon R, et al
    Recommendations for laboratory testing of UK patients with acute myeloid leukaemia.
    Br J Haematol. 2023;200:150-159.
    >> Share

  190. BOUKOUACI W, Rivera-Franco MM, Volt F, Wu CL, et al
    Comparative analysis of the variability of the human leukocyte antigen peptide-binding pockets in patients with acute leukaemia.
    Br J Haematol. 2023;200:197-209.
    >> Share

  191. PEREIRA-MARTINS DA, Coelho-Silva JL, Weinhauser I, Franca-Neto PL, et al
    Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.
    Br J Haematol. 2023;200:170-174.
    >> Share

  192. ROY L, Chomel JC, Guilhot J, Guerci-Bresler A, et al
    Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
    Br J Haematol. 2023;200:175-186.
    >> Share

    December 2022
  193. LI H, Xiang X, Ding H, Yu J, et al
    Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.
    Br J Haematol. 2022;199:768-771.
    >> Share

  194. CANALI A, Rieu JB
    Morphological characterization of acute myeloid leukaemia with t(11;17)(q23;q21)/ZBTB16::RARA fusion.
    Br J Haematol. 2022;199:638.
    >> Share

  195. WEI S, Gu R, Song Y, Yan Z, et al
    Early-salvage therapy with venetoclax-based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients.
    Br J Haematol. 2022;199:772-776.
    >> Share

  196. ATKINS O, Mirvis E, Maynard S, Katsomitrou V, et al
    Acute myeloid leukaemia presenting with Sweet syndrome.
    Br J Haematol. 2022;199:637.
    >> Share

  197. MUNIR T, Emmerson J, Hockaday A, Oughton JB, et al
    Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
    Br J Haematol. 2022;199:707-719.
    >> Share

  198. COPLAND M
    Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
    Br J Haematol. 2022;199:665-678.
    >> Share

    November 2022
  199. DONG Q, Wang Y, Xiu Y, Sakr H, et al
    Clonally related composite chronic lymphocytic leukaemia and mantle cell lymphoma.
    Br J Haematol. 2022 Nov 14. doi: 10.1111/bjh.18565.
    >> Share

  200. RIO-MACHIN A
    ATM serine/threonine kinase germline mutations in chronic lymphocytic leukaemia come in different flavours.
    Br J Haematol. 2022;199:307-309.
    >> Share

  201. PETRACKOVA A, Savara J, Turcsanyi P, Gajdos P, et al
    Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
    Br J Haematol. 2022;199:371-381.
    >> Share

  202. LI T, Wu P, Wang A, Chen M, et al
    A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia.
    Br J Haematol. 2022;199:305.
    >> Share

  203. FORDHAM NJ, Bartram J, Ghorashian S, O'Connor D, et al
    What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis?
    Br J Haematol. 2022;199:447-451.
    >> Share

  204. SHANMUGANATHAN N, Hughes TP
    Asciminib for chronic myeloid leukaemia: Next questions.
    Br J Haematol. 2022;199:322-331.
    >> Share

  205. WAN Y, Zhang H, Zhang L, Cai J, et al
    Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.
    Br J Haematol. 2022;199:587-596.
    >> Share

  206. WANG Y, Chen S, Chi P, Nie R, et al
    Survival prediction optimization of acute myeloid leukaemia based on T-cell function-related genes and plasma proteins.
    Br J Haematol. 2022;199:572-586.
    >> Share

  207. KRISTENSEN DT, Nielsen LB, Jakobsen LHK, Kristensen TC, et al
    Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study.
    Br J Haematol. 2022;199:539-548.
    >> Share

  208. ZHAO C, Wang S, Wang K
    Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia.
    Br J Haematol. 2022;199:e25-e29.
    >> Share

  209. QIANG X, Chen S, Chen X
    Peritoneal infiltration by leukaemic promyelocytes in acute promyelocytic leukaemia at initial diagnosis.
    Br J Haematol. 2022;199:475.
    >> Share

  210. KOTMAYER L, Romero-Moya D, Marin-Bejar O, Kozyra E, et al
    GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.
    Br J Haematol. 2022;199:482-495.
    >> Share

    October 2022
  211. ANDERSSON NG, Rathe M, Molle I, Jarvis KB, et al
    A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management.
    Br J Haematol. 2022;199:117-121.
    >> Share

  212. BARRETT J
    Screening for mercaptopurine intolerance in ALL - target the genes or their product?
    Br J Haematol. 2022;199:173-174.
    >> Share

  213. DENNIS M, Copland M, Kaur H, Kell J, et al
    Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
    Br J Haematol. 2022;199:205-221.
    >> Share

  214. TANAKA Y, Urayama KY, Mori M, Arakawa Y, et al
    Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;199:260-269.
    >> Share

  215. YOSHIDA M, Brown SA, Moriyama T, Nishii R, et al
    Low NUDT15 expression levels due to biallelic NUDT15 variants and 6-mercaptopurine intolerance.
    Br J Haematol. 2022;199:270-276.
    >> Share

  216. DILLON J, Mykytiv V, Keenan C, Mullaney B, et al
    Management of a patient with acute myeloid leukaemia with a diagnosis of type 2 von Willebrand disease and a novel variant within the von Willebrand factor (VWF) gene.
    Br J Haematol. 2022;199:e5-e7.
    >> Share

  217. ALSOUQI A, Rothenberger SD, Boyiadzis M, Lontos K, et al
    Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database.
    Br J Haematol. 2022;199:256-259.
    >> Share

  218. HAMPEL PJ, Rabe KG, Call TG, Ding W, et al
    Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2022;199:239-244.
    >> Share

    September 2022
  219. GREINER J, Goetz M, Schuler PJ, Bulach C, et al
    Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.
    Br J Haematol. 2022;198:866-874.
    >> Share

  220. YEOH DK, Blyth CC, Kotecha RS
    Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.
    Br J Haematol. 2022;198:887-892.
    >> Share

  221. ALBERTSEN BK, Lynggaard LS, Schmiegelow K
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:e84-e85.
    >> Share

  222. BRECCIA M, Olimpieri PP, Celant S, Olimpieri O, et al
    Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
    Br J Haematol. 2022;198:965-973.
    >> Share

  223. LI J, Liu L, Zhang R, Wan Y, et al
    Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia.
    Br J Haematol. 2022;198:1041-1050.
    >> Share

  224. VAN DER SLUIS IM, Bertrand Y, Baruchel A, Pieters R, et al
    Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?
    Br J Haematol. 2022;198:e82-e83.
    >> Share

  225. MOGENSEN N, Saaranen E, Olsson E, Klug Albertsen B, et al
    Quality of life in mothers and fathers of children treated for acute lymphoblastic leukaemia in Sweden, Finland and Denmark.
    Br J Haematol. 2022;198:1032-1040.
    >> Share

  226. MOPPETT J
    Metabolomics: A biomarker to improve the assessment of central nervous system positive acute lymphoblastic leukaemia?
    Br J Haematol. 2022;198:939-940.
    >> Share

  227. TAYLOR GP, Cook LB
    A new paradigm for the management of ATL.
    Br J Haematol. 2022;198:941-942.
    >> Share

  228. FAVINI C, Talotta D, Almasri M, Andorno A, et al
    Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
    Br J Haematol. 2022;198:1016-1022.
    >> Share

  229. HARRINGTON P, Dillon R, Radia D, McLornan D, et al
    Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.
    Br J Haematol. 2022;198:1011-1015.
    >> Share

  230. SONG Z, Tang G, Zhuang C, Wang Y, et al
    Metabolomic profiling of cerebrospinal fluid reveals an early diagnostic model for central nervous system involvement in acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:994-1010.
    >> Share

    August 2022
  231. NAKHODA S, Vistarop A, Wang YL
    Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Br J Haematol. 2022 Aug 27. doi: 10.1111/bjh.18418.
    >> Share

  232. ISIDORI A, Loscocco F, Visani G, Paolasini S, et al
    Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
    Br J Haematol. 2022 Aug 24. doi: 10.1111/bjh.18426.
    >> Share

  233. IMBERY JF, Heinzelbecker J, Jebsen JK, McGowan M, et al
    T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation.
    Br J Haematol. 2022;198:556-573.
    >> Share

  234. WANG X, Tang G, Hu Z, Fang H, et al
    Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival.
    Br J Haematol. 2022;198:604-608.
    >> Share

  235. SANCHEZ-VIZCAINO F, Tamayo C, Ramos F, Lainez-Gonzalez D, et al
    Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study.
    Br J Haematol. 2022;198:545-555.
    >> Share

  236. LU L, Kok CH, Dang P, Branford S, et al
    Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission.
    Br J Haematol. 2022;198:600-603.
    >> Share

  237. PODVIN B, Guermouche H, Fournier E, Berthon C, et al
    Acute myeloid leukaemia with double minute chromosomes encompassing the 8q24 region.
    Br J Haematol. 2022;198:413.
    >> Share

  238. CHAN WY, Zhu C, Sanchez E, Gupta R, et al
    Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.
    Br J Haematol. 2022;198:478-481.
    >> Share

  239. HERAUDET L, Galtier J, Favre S, Peyraud F, et al
    VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
    Br J Haematol. 2022;198:523-527.
    >> Share

  240. JAMY O, Lin K, Worth S, Bachiashvili K, et al
    Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2022;198:e35-e37.
    >> Share

  241. ALHAJ ISSA Z, Altwijri A, Alfayez M
    Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia.
    Br J Haematol. 2022;198:414.
    >> Share

  242. ADES L, Duployez N, Guerci-Bresler A, Laribi K, et al
    A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
    Br J Haematol. 2022;198:535-544.
    >> Share

  243. RUSSELL NH, Hills RK, Kjeldsen L, Clark RE, et al
    A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
    Br J Haematol. 2022;198:528-534.
    >> Share

  244. VALTIS YK, Place AE, Silverman LB, Vrooman LM, et al
    Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:421-430.
    >> Share

  245. VOLPE VO, Al Ali N, Chan O, Padron E, et al
    Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
    Br J Haematol. 2022;198:713-720.
    >> Share

  246. MULLIGAN SP, Opat S, Marlton P, Kuss B, et al
    Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2022;198:790-793.
    >> Share

  247. GENTHON A, Dragoi D, Memoli M, Hirsch P, et al
    Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2022;198:780-784.
    >> Share

  248. LAURA CS, Ana FM, Ines LH
    Pure erythroid leukaemia mimicking metastatic carcinoma.
    Br J Haematol. 2022;198:617.
    >> Share

    July 2022
  249. STRATI P, Coleman M, Champion R, Ma S, et al
    A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18368.
    >> Share

  250. ROLDAN GALIACHO V, Zaldumbide Duenas L, Lobo Olmedo A, Alonso Varela M, et al
    Intracytoplasmic crystalline inclusions in peripheral blood lymphocytes in small lymphocytic lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18380.
    >> Share

  251. MEYER LK, Delgado-Martin C, Sharp PP, Huang BJ, et al
    Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:137-141.
    >> Share

  252. GHANDILI S, Kluger MA, Leitner T, Grahammer F, et al
    Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation.
    Br J Haematol. 2022;198:199-202.
    >> Share

  253. KRIEL M, Opie J, Louw V, Musekwa E, et al
    Clover leaf nuclear morphology in chronic lymphocytic leukaemia with typical immunophenotype and absence of trisomy 12.
    Br J Haematol. 2022;198:8.
    >> Share

  254. PIMENTEL-VILLAR MA, Morales-Camacho RM, Vargas MT, Jimenez-Jambrina M, et al
    Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1.
    Br J Haematol. 2022;198:7.
    >> Share

  255. CLAXTON DF
    Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment.
    Br J Haematol. 2022;198:9-10.
    >> Share

  256. SIDHU J, Masurekar AN, Gogoi MP, Fong C, et al
    Activity and toxicity of intramuscular 1000 iu/m(2) polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.
    Br J Haematol. 2022;198:142-150.
    >> Share

  257. WANG J, Jiang H, Jing Y, Su L, et al
    Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Br J Haematol. 2022;198:e3-e8.
    >> Share

  258. VOSO MT, Pandzic T, Falconi G, Dencic-Fekete M, et al
    Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
    Br J Haematol. 2022;198:103-113.
    >> Share

  259. DE PROPRIS MS, Musiu P, Intoppa S, Nardacci MG, et al
    Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall.
    Br J Haematol. 2022;198:e28-e31.
    >> Share

  260. STENGEL S, Petrie KR, Sbirkov Y, Stanko C, et al
    Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
    Br J Haematol. 2022;198:338-348.
    >> Share

  261. DHUNPUTH C, Strullu M, Petit A, Merched M, et al
    Single-dose (4.5 mg/m(2) ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia.
    Br J Haematol. 2022;198:373-381.
    >> Share

  262. SHIVAROV V, Grigorova D
    Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia.
    Br J Haematol. 2022;198:e23-e25.
    >> Share

  263. GUO JJ, Cao L, Zhu HY, Miao Y, et al
    T-cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single-centre retrospective analysis of 17 cases.
    Br J Haematol. 2022;198:e18-e22.
    >> Share

    June 2022
  264. KATAYAMA S, Hiraishi T, Ota M
    Skin manifestations of intravascular adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2022 Jun 27. doi: 10.1111/bjh.18318.
    >> Share

  265. BRIVIO E, Cossio A, Borra D, Silvestri D, et al
    Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort.
    Br J Haematol. 2022;197:602-608.
    >> Share

  266. WALEWSKA R, Parry-Jones N, Eyre TA, Follows G, et al
    Guideline for the treatment of chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:544-557.
    >> Share

  267. MOIA R, Gaidano G
    Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:513-514.
    >> Share

  268. WANG QQ, Wang HF, Zhao JZ, Naranmandura H, et al
    Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e58-e60.
    >> Share

  269. MERLI P
    Treating second-relapsed/refractory first-relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
    Br J Haematol. 2022;197:651-652.
    >> Share

  270. WANG M, Lin H, Chu X, Wang Z, et al
    Identification of a recurrent fusion NUP98-RARG in acute myeloid leukaemia resembling acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e73-e78.
    >> Share

  271. LYNGGAARD LS, Vaitkeviciene G, Langenskiold C, Lehmann AK, et al
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:745-754.
    >> Share

  272. TARIQ H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, et al
    Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
    Br J Haematol. 2022;197:736-744.
    >> Share

  273. MORI A, Onozawa M, Tsukamoto S, Ishio T, et al
    Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
    Br J Haematol. 2022;197:691-696.
    >> Share

  274. WHITE T, Kaspers G, Abrahamsson J, Arad-Cohen N, et al
    Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO-DB SHIP consortium.
    Br J Haematol. 2022;197:755-765.
    >> Share

    May 2022
  275. SHICHIJO T, Nosaka K, Tatetsu H, Higuchi Y, et al
    Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2022 May 24. doi: 10.1111/bjh.18281.
    >> Share

  276. ZHU K, Jamroz A, Huang S, Villa D, et al
    Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Br J Haematol. 2022 May 14. doi: 10.1111/bjh.18241.
    >> Share

  277. JOBSON D, McCormack CJ, Mar V, Tam C, et al
    Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.
    Br J Haematol. 2022;197:320-325.
    >> Share

  278. TAYLOR T, Byrne J, Errico G, Clark D, et al
    Very late extramedullary relapse of acute myeloid leukaemia as prostatic myeloid sarcoma occurring 24 years post-allograft.
    Br J Haematol. 2022;197:243.
    >> Share

  279. OLIVEIRA AF, Tansini A, Toledo T, Balceiro R, et al

    Br J Haematol. 2022;197:339-348.
    >> Share

  280. UJJANI C, Shadman M, Lynch RC, Tu B, et al
    The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:306-309.
    >> Share

  281. CARTWRIGHT A, Scott S, Francis S, Whitby L, et al
    Assessing the impact of the 2017 European LeukemiaNet recommendations on FLT3 allelic ratio calculation and reporting in acute myeloid leukaemia.
    Br J Haematol. 2022;197:e35-e37.
    >> Share

  282. PETERSEN MA, Rosenberg CA, Brondum RF, Aggerholm A, et al
    Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups.
    Br J Haematol. 2022;197:452-466.
    >> Share

  283. WEI H, Zhou C, Liu B, Lin D, et al
    The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
    Br J Haematol. 2022;197:442-451.
    >> Share

  284. LEW TE, Anderson MA
    Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies.
    Br J Haematol. 2022;197:394-396.
    >> Share

  285. OERLEMANS S, Efficace F, Kieffer JM, Kyriakou C, et al
    International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:431-441.
    >> Share

  286. JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
    Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:475-481.
    >> Share

  287. ALTER BP, Giri N, McReynolds LJ, Altintas B, et al
    Fanconi anaemia: A syndrome with distinct subgroups.
    Br J Haematol. 2022;197:467-474.
    >> Share

  288. YU Q, Yu D, Chen X
    Cup-shaped nuclei in acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:389.
    >> Share

    April 2022
  289. SUN C
    COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion.
    Br J Haematol. 2022;197:11-12.
    >> Share

  290. SHEN Y, Freeman JA, Holland J, Solterbeck A, et al
    COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
    Br J Haematol. 2022;197:41-51.
    >> Share

  291. CLAUDIANI S, Apperley JF, Parker EL, Marchesin F, et al
    Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
    Br J Haematol. 2022;197:e1-e4.
    >> Share

  292. ON S, Rath CG, Lan M, Wu B, et al
    Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
    Br J Haematol. 2022;197:63-70.
    >> Share

  293. GADI D, Griffith A, Wang Z, Tyekucheva S, et al
    Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:207-211.
    >> Share

  294. RECKZEH K, Estruch M, Ali M, Sogaard Helbo A, et al
    TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.
    Br J Haematol. 2022;197:201-206.
    >> Share

  295. BRANFORD S
    BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
    Br J Haematol. 2022;197:9-10.
    >> Share

  296. DOMINY KM, Claudiani S, O'Hare M, Szydlo R, et al
    Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
    Br J Haematol. 2022;197:52-62.
    >> Share

  297. VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
    Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Br J Haematol. 2022;197:76-81.
    >> Share

  298. HILLS RK
    Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?
    Br J Haematol. 2022;197:e26-e27.
    >> Share

  299. YEUNG DTO, Osborn MP, White DL
    B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
    Br J Haematol. 2022;197:13-27.
    >> Share

  300. TONG WH
    Does anticoagulation prophylaxis reduce the rate of venous thromboembolism in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy?
    Br J Haematol. 2022;197:e24-e25.
    >> Share

  301. JENSEN K, Oskarsson T, Lahteenmaki P, Flaegstad T, et al
    Doing less, accomplishing more for childhood ALL: response.
    Br J Haematol. 2022;197:120.
    >> Share

    March 2022
  302. CULL G, Burger JA, Opat S, Gottlieb D, et al
    Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
    Br J Haematol. 2022;196:1209-1218.
    >> Share

  303. MORIYA K, Imamura T, Katayama S, Kaino A, et al
    The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Munster (BFM)95-based protocol.
    Br J Haematol. 2022;196:1257-1261.
    >> Share

  304. MAAS CCHM, van Klaveren D, Ector GICG, Posthuma EFM, et al
    The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
    Br J Haematol. 2022;196:1219-1224.
    >> Share

  305. BARZILAI-BIRENBOIM S, Elitzur S, Nirel R, Ehrenberg M, et al
    Elevated intraocular pressure in children with acute lymphoblastic leukaemia: A prospective study.
    Br J Haematol. 2022;196:1248-1256.
    >> Share

  306. DILLON R, Hills RK, Burnett AK, Russell NH, et al
    Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
    Br J Haematol. 2022;196:e50-e52.
    >> Share

  307. WALDRON C, O'Brien D, Brophy S, Perera K, et al
    Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning.
    Br J Haematol. 2022;196:e47-e49.
    >> Share

  308. EGNELL C, Heyman M, Jonsson OG, Raja RA, et al
    Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:1239-1247.
    >> Share

  309. GALLIPOLI P, Clark RE, Byrne J, Apperley JF, et al
    The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
    Br J Haematol. 2022;196:e55-e57.
    >> Share

  310. COATS T, Bean D, Basset A, Sirkis T, et al
    A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
    Br J Haematol. 2022;196:1337-1343.
    >> Share

  311. SALHOTRA A, Tsai NC, Zhang J, Ngo D, et al
    Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2022;196:e71-e74.
    >> Share

  312. RUSSELL N, Hills R, Kjeldsen L, Dennis M, et al
    Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
    Br J Haematol. 2022;196:1344-1347.
    >> Share

  313. MCCLURE BJ, Pal M, Heatley SL, Rehn J, et al
    Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features.
    Br J Haematol. 2022;196:1407-1411.
    >> Share

  314. LINCH DC, Hills RK, Burnett AK, Russell N, et al
    Therapy for isocitrate dehydrogenase 2 (IDH2)(R172) -mutant acute myeloid leukaemia.
    Br J Haematol. 2022;196:1348-1352.
    >> Share

  315. BENDE RJ, Janssen J, van Noesel CJM
    Higher-order of chronic lymphocytic leukaemia (CLL) classification: shared antigenic specificities of stereotyped B-cell receptor subsets as defined by the European Research Initiative on CLL consortium.
    Br J Haematol. 2022;196:e60-e63.
    >> Share

  316. TAWANA K, Brown AL, Churpek JE
    Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges.
    Br J Haematol. 2022;196:1293-1310.
    >> Share

    February 2022
  317. CLAUDIANI S
    Is COVID-19 less severe in CML patients than in those with other haematological cancers?
    Br J Haematol. 2022;196:471-472.
    >> Share

  318. BRECCIA M, Abruzzese E, Accurso V, Attolico I, et al
    COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
    Br J Haematol. 2022;196:559-565.
    >> Share

  319. SCHENKER C, Hirzel C, Walti LN, Zeerleder SS, et al
    Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
    Br J Haematol. 2022;196:e27-e29.
    >> Share

  320. BIONDI A, Conter V, Chandy M, Ewald P, et al
    Precursor B-cell acute lymphoblastic leukaemia-a global view.
    Br J Haematol. 2022;196:530-547.
    >> Share

  321. SALEK C, Folber F, Fronkova E, Pecherkova P, et al
    Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.
    Br J Haematol. 2022;196:706-710.
    >> Share

  322. DOWNES CEJ, Rehn J, Heatley SL, Yeung D, et al
    Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:700-705.
    >> Share

  323. SCHWAB CJ, Murdy D, Butler E, Enshaei A, et al
    Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
    Br J Haematol. 2022;196:753-763.
    >> Share

  324. TANDON S, Visser R, Astwood E, Payne J, et al
    Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature.
    Br J Haematol. 2022;196:e34-e39.
    >> Share

  325. KRIEG S, Seeger H, Hofmann P, Del Prete C, et al
    Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia.
    Br J Haematol. 2022;196:781-784.
    >> Share

  326. VOJDEMAN FJ, Helby J, Pedersen LB, Brieghel C, et al
    Chronic lymphocytic leukaemia clones are detectable decades before diagnosis.
    Br J Haematol. 2022;196:784-787.
    >> Share

  327. HUANG W, Sundquist K, Sundquist J, Ji J, et al
    Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
    Br J Haematol. 2022;196:690-699.
    >> Share

  328. RIBERA J, Granada I, Morgades M, Gonzalez T, et al
    Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
    Br J Haematol. 2022;196:670-675.
    >> Share

  329. BOOTH S, Curley HM, Varnai C, Arnold R, et al
    Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
    Br J Haematol. 2022;196:892-901.
    >> Share

  330. ALLAN JN, Shanafelt T, Wiestner A, Moreno C, et al
    Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    Br J Haematol. 2022;196:947-953.
    >> Share

  331. AHMED HMM, Nimmagadda SC, Al-Matary YS, Fiori M, et al
    Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells.
    Br J Haematol. 2022;196:995-1006.
    >> Share

  332. SHEN Z, Zhou M, Zhang J, Chen S, et al
    Microgranular variant of acute promyelocytic leukaemia with an unusual T/myeloid immunophenotype resembling that of mixed-phenotype acute leukaemia.
    Br J Haematol. 2022;196:801.
    >> Share

  333. ABDEL RAHMAN ZH, Parrondo RD, Heckman MG, Wieczorek M, et al
    Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:963-968.
    >> Share

  334. EYRE TA, Riches JC, Patten PEM, Walewska R, et al
    Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper.
    Br J Haematol. 2022;196:864-870.
    >> Share

    January 2022
  335. TOMOWIAK C, Leblond V, Laribi K, Baron M, et al
    Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstrom macroglobulinemia: a French Innovative Leukemia Organization (FILO) study.
    Br J Haematol. 2022 Jan 14. doi: 10.1111/bjh.18055.
    >> Share

  336. NAVILLE AS, Lazaro E, Boutin J, Prot-Leurent C, et al
    Acquired glucose 6-phosphate dehydrogenase (G6PD) deficiency in a patient with Chronic Myelomonocytic Leukemia.
    Br J Haematol. 2022 Jan 6. doi: 10.1111/bjh.18037.
    >> Share

  337. SAULTIER P, Ninove L, Szepetowski S, Veneziano M, et al
    Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
    Br J Haematol. 2022;196:e1-e3.
    >> Share

  338. MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
    The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Br J Haematol. 2022;196:362-367.
    >> Share

  339. GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
    Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Br J Haematol. 2022;196:360-362.
    >> Share

  340. SEVIAR D, Nyunt K, Sayer C, Wright D, et al
    Romboutsia-induced bone marrow necrosis at presentation of acute myeloid leukaemia.
    Br J Haematol. 2022;196:262.
    >> Share

  341. YAO H, Huo L, Ping N, Liu H, et al
    Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia.
    Br J Haematol. 2022;196:441-444.
    >> Share

  342. KIM DDH, Kim TS, Atenafu EG, Novitzky Basso I, et al
    BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
    Br J Haematol. 2022;196:136-145.
    >> Share

  343. LOKE J, Metzner M, Boucher R, Jackson A, et al
    Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
    Br J Haematol. 2022;196:368-373.
    >> Share

  344. PODVIN B, Goursaud L, Roynard P, Nibourel O, et al
    Chronic myeloid leukaemia presenting with monocytosis.
    Br J Haematol. 2022;196:8.
    >> Share

  345. NAKAJIMA R, Matsuo T, Sumiyoshi R, Saito S, et al
    Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib.
    Br J Haematol. 2022;196:e9-e11.
    >> Share

  346. KAYSER S, Levis MJ
    Updates on targeted therapies for acute myeloid leukaemia.
    Br J Haematol. 2022;196:316-328.
    >> Share

  347. MIKHAILOVA E, Roumiantseva J, Illarionova O, Lagoyko S, et al
    Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
    Br J Haematol. 2022;196:e6-e9.
    >> Share

  348. SHANMUGANATHAN N, Branford S
    Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing.
    Br J Haematol. 2022;196:19-30.
    >> Share

    December 2021
  349. FOX TA, Kirkwood AA, Enfield L, O'Reilly M, et al
    Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
    Br J Haematol. 2021;195:706-709.
    >> Share

  350. KIM HS, Lee JW, Kang D, Yu H, et al
    Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Br J Haematol. 2021;195:748-756.
    >> Share

  351. MINGUELA A, Salido EJ, Soto-Ramirez MF, Olga MA, et al
    Low-affinity immunoglobulin gamma Fc region receptor III-B (FcgammaRIIIB, CD16B) deficiency in patients with blood and immune system disorders.
    Br J Haematol. 2021;195:743-747.
    >> Share

  352. SILLA L, Valim V, Pezzi A, da Silva M, et al
    Adoptive immunotherapy with double-bright (CD56(bright) /CD16(bright) ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study.
    Br J Haematol. 2021;195:710-721.
    >> Share

  353. TANG FF, Lu SY, Zhao XS, Qin YZ, et al
    PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort stud
    Br J Haematol. 2021;195:722-730.
    >> Share

    November 2021
  354. FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
    Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
    Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.
    >> Share

  355. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    >> Share

  356. SHIMONI A, Robin M, Iacobelli S, Beelen D, et al
    Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    Br J Haematol. 2021;195:417-428.
    >> Share

  357. HWANG J, Singh N, Braniecki M, Gok Yavuz B, et al
    Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
    Br J Haematol. 2021;195:e138-e141.
    >> Share

  358. SMYTH L, Blunt DN, Cheung MC
    Statins in mature B-cell lymphomas and leukaemias.
    Br J Haematol. 2021;195:490-492.
    >> Share

  359. SOLANO DE LA ASUNCION C, Terol MJ, Saus A, Olea B, et al
    Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
    Br J Haematol. 2021;195:637-641.
    >> Share

  360. BEGNA KH, Kittur J, Yui J, Gangat N, et al
    De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases.
    Br J Haematol. 2021;195:413-416.
    >> Share

  361. ZHONG ZQ, Zhuang HF, Wu SL, Zhang H, et al
    Pseudo-Chediak-Higashi inclusions in relapsed acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:300.
    >> Share

  362. SKOU AS, Juul-Dam KL, Ommen HB, Hasle H, et al
    Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
    Br J Haematol. 2021;195:310-327.
    >> Share

    October 2021
  363. NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
    Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
    >> Share

  364. LIU M, Zhao X, Pan W, Qian Z, et al
    A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy.
    Br J Haematol. 2021;195:e123-e128.
    >> Share

  365. BARTRAM J, Balasch-Carulla M, Bhojaraja S, Adams S, et al
    Blinatumomab for paediatric mixed phenotype acute leukaemia.
    Br J Haematol. 2021;195:289-292.
    >> Share

  366. EDWARDS K, Zaitseva K, Sayed U, Volpi EV, et al
    Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;195:e131-e134.
    >> Share

  367. TESTI AM, Mohamed S, Diverio D, Piciocchi A, et al
    Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
    Br J Haematol. 2021;195:278-283.
    >> Share

  368. BEZDEKOVA R, Jelinek T, Kralova R, Stork M, et al
    Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
    Br J Haematol. 2021;195:95-107.
    >> Share

  369. GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
    Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
    Br J Haematol. 2021;195:113-118.
    >> Share

  370. THASTRUP M, Marquart HV, Levinsen M, Modvig S, et al
    Flow cytometric analysis of cerebrospinal fluid improves detection of leukaemic blasts in infants with acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:119-122.
    >> Share

  371. O'CONNOR D, Loke J, Brown M, Stanworth SJ, et al
    Non-pharmacological supportive-care interventions in acute myeloid leukaemia: a review of randomised controlled trials.
    Br J Haematol. 2021;195:e97-e113.
    >> Share

  372. MAENG CV, Ostgard LSG, Christiansen CF, Liu KD, et al
    Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12-year period: a Danish nationwide cohort study.
    Br J Haematol. 2021;195:137-140.
    >> Share

    September 2021
  373. COOK LBM
    Adult T-cell leukaemia/lymphoma and the trouble with TP53.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.
    >> Share

  374. CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
    Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
    >> Share

  375. CHOWDHURY O, Bruguier H, Mallett G, Sousos N, et al
    Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
    Br J Haematol. 2021;194:1010-1015.
    >> Share

  376. HARRINGTON P, Doores KJ, Radia D, O'Reilly A, et al
    Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;194:999-1006.
    >> Share


  377. A special issue on modern genomics in diagnostic haematology.
    Br J Haematol. 2021;194:801-802.
    >> Share

  378. KUIPER RP, Hoogeveen PG, Bladergroen R, van Dijk F, et al
    Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.
    Br J Haematol. 2021;194:888-892.
    >> Share

  379. KHAN M, Roddy JT, Hernandez JR, Bursch K, et al
    Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML.
    Br J Haematol. 2021;194:1083-1085.
    >> Share

  380. RASCHE A, Mason EF, Strickland SA, Byrne M, et al
    Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;194:927-931.
    >> Share

  381. ALCALDE-MELLADO P, Franco-Macias E, Morales-Camacho RM, Caballero-Velazquez T, et al
    Auer rod-like inclusions in cerebrospinal fluid in accelerated phase chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:946.
    >> Share

    August 2021
  382. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    >> Share

  383. FANG H, Wang W, El Hussein S, Morita K, et al
    B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
    Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
    >> Share

  384. HENRY A, Bracquemart C, Naguib D, Chantepie S, et al
    Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17761.
    >> Share

  385. PATEL PA, Lapp SA, Grubbs G, Edara VV, et al
    Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
    Br J Haematol. 2021;194:549-553.
    >> Share

  386. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.
    >> Share

  387. YEOH AEJ, Oh BL, Ariffin H
    Doing less, accomplishing more for childhood acute lymphoblastic leukaemia (ALL).
    Br J Haematol. 2021;194:661-662.
    >> Share

  388. NOURA M, Morita K, Kiyose H, Okuno Y, et al
    Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Kruppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) axis.
    Br J Haematol. 2021;194:598-603.
    >> Share

  389. RAMDENY PS, Mullanfroze K, de Lorenzo P, Grazia Valsecchi M, et al
    Infant T-cell acute lymphoblastic leukaemia with t(6;7) (TCRB-MYB) translocation.
    Br J Haematol. 2021;194:613-616.
    >> Share

  390. ROMZOVA M, Smitalova D, Hynst J, Tom N, et al
    Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
    Br J Haematol. 2021;194:604-612.
    >> Share

  391. MASLAH N, Diawara Y, Sebert M, Giraudier S, et al
    In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
    Br J Haematol. 2021;194:e77-e79.
    >> Share

  392. JENSEN KS, Oskarsson T, Lahteenmaki PM, Flaegstad T, et al
    Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population-based cohort study.
    Br J Haematol. 2021;194:734-744.
    >> Share

  393. CORNEAU A, Parizot C, Cherai M, Todesco E, et al
    Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
    Br J Haematol. 2021;194:788-792.
    >> Share

  394. ALLSUP D, Howard D, Emmerson J, Hockaday A, et al
    COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
    Br J Haematol. 2021;194:646-650.
    >> Share

  395. LOBO-OLMEDO A, Roldan Galiacho V, Arzuaga-Mendez J, Ancin I, et al
    Acute megakaryoblastic leukaemia with erythrophagocytosis.
    Br J Haematol. 2021;194:658.
    >> Share

    July 2021
  396. BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
    Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
    >> Share

  397. MOIA R, Favini C, Ferri V, Forestieri G, et al
    Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
    >> Share

  398. HEHLMANN R
    What is the right dosage of dasatinib for treating chronic myeloid leukaemia?
    Br J Haematol. 2021;194:234.
    >> Share

  399. ROUSSELOT P, Mollica L, Guilhot J, Guerci A, et al
    Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
    Br J Haematol. 2021;194:393-402.
    >> Share

  400. NAKAMURA M, Arai Y, Hirabayashi S, Kondo T, et al
    Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.
    Br J Haematol. 2021;194:403-413.
    >> Share

  401. COMONT T, Meunier M, Cherait A, Santana C, et al
    Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Br J Haematol. 2021;194:336-343.
    >> Share

  402. WIERNIK PH, Sun Z, Cripe LD, Rowe JM, et al
    Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia.
    Br J Haematol. 2021;194:309-318.
    >> Share

  403. ROEKER LE, Thompson MC, Mato AR
    Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice.
    Br J Haematol. 2021;194:9-10.
    >> Share

  404. MULRONEY CM, Abid MB, Bashey A, Chemaly RF, et al
    Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
    Br J Haematol. 2021;194:145-157.
    >> Share

  405. EYRE TA, Preston G, Kagdi H, Islam A, et al
    A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
    Br J Haematol. 2021;194:69-77.
    >> Share

  406. SASAKI K, Tsujimoto S, Miyake M, Uchiyama Y, et al
    Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
    Br J Haematol. 2021;194:414-422.
    >> Share

  407. SCOTT S, Cartwright A, Francis S, Whitby L, et al
    Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
    Br J Haematol. 2021;194:53-60.
    >> Share

  408. RADICH J
    Building a better mousetrap for accurate and sensitive polymerase chain reaction.
    Br J Haematol. 2021;194:11-13.
    >> Share

  409. SASSEN SDT, Mathot RAA, Pieters R, de Haas V, et al
    Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.
    Br J Haematol. 2021;194:423-432.
    >> Share

  410. KOUKOULIAS K, Papadopoulou A, Kouimtzidis A, Papayanni PG, et al
    Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.
    Br J Haematol. 2021;194:158-167.
    >> Share

  411. BODOR C, Kotmayer L, Laszlo T, Takacs F, et al
    Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
    Br J Haematol. 2021;194:355-364.
    >> Share

  412. MICHALOWSKI MB, Cecconello DK, Lins MM, Carvalho MDPSS, et al
    Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study.
    Br J Haematol. 2021;194:168-173.
    >> Share

  413. ZHAO Y, McCracken J, Rehder C, Wang E, et al
    Biclonal evolution of chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:e64-e66.
    >> Share

  414. CHERNG HJ, Jammal N, Paul S, Wang X, et al
    Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:61-68.
    >> Share

  415. DENNIS M, Burnett A, Hills R, Thomas I, et al
    A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    Br J Haematol. 2021;194:298-308.
    >> Share

  416. POCOCK R, Farah N, Richardson SE, Mansour MR, et al
    Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;194:28-43.
    >> Share

  417. ASSANTO GM, Riemma C, Malaspina F, Perrone S, et al
    The current role of interferon in hairy cell leukaemia: clinical and molecular aspects.
    Br J Haematol. 2021;194:78-82.
    >> Share

  418. POPOV A, Fominikh V, Mikhailova E, Shelikhova L, et al
    Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants.
    Br J Haematol. 2021;194:174-178.
    >> Share

  419. KOLLA BC, Halim NAA, Cao Q, Sachs Z, et al
    High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
    Br J Haematol. 2021;194:140-144.
    >> Share

  420. HSU H, Roncolato F, Lee SH
    Lysosomal acid lipase deficiency diagnosed in a patient presenting with acute myeloid leukaemia.
    Br J Haematol. 2021;194:228.
    >> Share

  421. SHACKLETON L, McCarthy J, Mykytiv V
    Extramedullary pericardial haematopoiesis as a presenting feature of chronic myeloid leukaemia.
    Br J Haematol. 2021;194:7.
    >> Share

    June 2021
  422. OSTERGAARD J, Jonart LM, Ebadi M, Koppenhafer SL, et al
    Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17610.
    >> Share

  423. KARANTANOS T, Gondek LP, Varadhan R, Moliterno AR, et al
    Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Br J Haematol. 2021;193:1142-1150.
    >> Share

  424. XU R, Huang X, Li C, Deng C, et al
    Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/beta-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
    Br J Haematol. 2021;193:928-940.
    >> Share

  425. MOSKORZ W, Cosmovici C, Jager PS, Cadeddu RP, et al
    Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
    Br J Haematol. 2021;193:941-945.
    >> Share

  426. CAO H, Neerincx A, de Bono B, Lakner U, et al
    Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.
    Br J Haematol. 2021;193:946-950.
    >> Share

  427. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    >> Share

  428. NISHIMURA A, Naruto T, Miyamoto S, Grigg A, et al
    Genomics analysis of leukaemia predisposition in X-linked agammaglobulinaemia.
    Br J Haematol. 2021;193:1277-1281.
    >> Share

  429. VAN DE GEER A, Zandstra J, Tanck MWT, Nur E, et al
    Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study.
    Br J Haematol. 2021;193:1008-1012.
    >> Share

  430. SHAH MV, Saliba RM, Varma A, Ciurea SO, et al
    Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
    Br J Haematol. 2021;193:1004-1008.
    >> Share

  431. FLYGT H, Sandin F, Dahlen T, Dremaine A, et al
    Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
    Br J Haematol. 2021;193:915-921.
    >> Share

  432. WANG H, Zhou Y, Huang X, Zhang Y, et al
    Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1096-1104.
    >> Share

  433. CREUZET E, Nourrisson C, Chaleteix C, Poirier P, et al
    Cerebral aspergillosis in a patient on ibrutinib therapy.
    Br J Haematol. 2021;193:1025.
    >> Share

  434. DANDER E, Fallati A, Gulic T, Pagni F, et al
    Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1157-1171.
    >> Share

  435. TSAUR G, Popov A, Riger T, Kustanovich A, et al
    Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Br J Haematol. 2021;193:1151-1156.
    >> Share

  436. BRIVIO E, Chantrain CF, Gruber TA, Thano A, et al
    Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
    Br J Haematol. 2021;193:1172-1177.
    >> Share

  437. BRAS AE, Osmani Z, de Haas V, Jongen-Lavrencic M, et al
    Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.
    Br J Haematol. 2021;193:922-927.
    >> Share

    May 2021
  438. CHANDER G, Nikolousis E, Kanellopoulos A
    Human papilloma virus (HPV)-associated lesions in a post-bone marrow transplant patient responding to HPV vaccination.
    Br J Haematol. 2021 May 2. doi: 10.1111/bjh.17514.
    >> Share

  439. ROSS DM
    How much imatinib is enough?
    Br J Haematol. 2021;193:699-700.
    >> Share

  440. KIM DDH, Novitzky-Basso I, Kim TS, Atenafu EG, et al
    Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
    Br J Haematol. 2021;193:779-791.
    >> Share

  441. KHARFAN-DABAJA MA, Labopin M, Brissot E, Kroger N, et al
    Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;193:592-601.
    >> Share

  442. AOKI K, Kurashige M, Ichii M, Higaki K, et al
    Identification of CXCL12-abundant reticular cells in human adult bone marrow.
    Br J Haematol. 2021;193:659-668.
    >> Share

  443. MIKHAILOVA E, Semchenkova A, Illarionova O, Kashpor S, et al
    Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
    Br J Haematol. 2021;193:602-612.
    >> Share

  444. SEMBILL S, Gohring G, Schirmer E, Lutterloh F, et al
    Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics.
    Br J Haematol. 2021;193:613-618.
    >> Share

  445. DE MIGUEL SANCHEZ C, Robles de Castro D, Pison Herrero C, Perez Persona E, et al
    Primary plasma cell leukaemia presenting with flower-shaped nuclei.
    Br J Haematol. 2021;193:689.
    >> Share

  446. CHEN D, Chen W
    Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Br J Haematol. 2021;193:691.
    >> Share

  447. NOY-LOTAN S, Krasnov T, Dgany O, Jeison M, et al
    Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Br J Haematol. 2021;193:570-580.
    >> Share

  448. HJORT JAKOBSEN L, Stidsholt Roug A, Kiesbye Ovlisen A, Werenberg Marcher C, et al
    Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.
    Br J Haematol. 2021;193:482-487.
    >> Share

  449. SMOLEJ L
    Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    Br J Haematol. 2021;193:723-726.
    >> Share

    April 2021
  450. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    >> Share

  451. ZHENG J, Wu S, Hu Y, Gao L, et al
    Management of ETV6-ABL1-positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action.
    Br J Haematol. 2021;193:197-200.
    >> Share

  452. GANESAN P, Jain H, Bagal B, Subramanian PG, et al
    Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC).
    Br J Haematol. 2021;193:e1-e4.
    >> Share

  453. FITTER S, Bradey AL, Kok CH, Noll JE, et al
    CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:171-175.
    >> Share

  454. TROUSSARD X, Grever MR
    The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.
    Br J Haematol. 2021;193:11-14.
    >> Share

  455. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    >> Share

  456. SMOLEJ L, Turcsanyi P, Kubova Z, Zuchnicka J, et al
    External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.
    Br J Haematol. 2021;193:133-137.
    >> Share

  457. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    >> Share

  458. RASTOGI N, Baker S, Man S, Uger RA, et al
    Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
    Br J Haematol. 2021;193:155-159.
    >> Share

  459. GURNARI C, Breccia M, Di Giuliano F, Scalzulli E, et al
    Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.
    Br J Haematol. 2021;193:129-132.
    >> Share

  460. STILGENBAUER S, Bosch F, Ilhan O, Kisro J, et al
    Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Br J Haematol. 2021;193:325-338.
    >> Share

  461. DA CUNHA-BANG C, Rostgaard K, Andersen MA, Rotbain EC, et al
    Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
    Br J Haematol. 2021;193:339-345.
    >> Share

  462. SOVERINI S, Martelli M, Bavaro L, De Benedittis C, et al
    Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:271-279.
    >> Share

  463. CLAUDIANI S, Apperley JF, Szydlo R, Khan A, et al
    TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;193:346-355.
    >> Share

  464. DILLON R, Potter N, Freeman S, Russell N, et al
    How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
    Br J Haematol. 2021;193:231-244.
    >> Share

    March 2021
  465. HASSERJIAN RP
    Flow cytometry reveals the nuances of clonal haematopoiesis.
    Br J Haematol. 2021;192:949-950.
    >> Share

  466. BECKER MW, Angelucci E
    A large co-operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia.
    Br J Haematol. 2021;192:800-802.
    >> Share

  467. LOGHAVI S, DiNardo CD, Furudate K, Takahashi K, et al
    Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
    Br J Haematol. 2021;192:1054-1063.
    >> Share

  468. SCHLIEMANN C, Kessler T, Berdel AF, Hemmerle T, et al
    Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
    Br J Haematol. 2021;192:e148-e151.
    >> Share

  469. FERRARI A, Ghelli Luserna Di Rora A, Domizio C, Papayannidis C, et al
    Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
    Br J Haematol. 2021;192:e139-e144.
    >> Share

  470. RIGOLIN GM, Saccenti E, Melandri A, Cavallari M, et al
    In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.
    Br J Haematol. 2021;192:1068-1072.
    >> Share

  471. TIONG IS, Dillon R, Ivey A, Teh TC, et al
    Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
    Br J Haematol. 2021;192:1026-1030.
    >> Share

  472. QU S, Li B, Qin T, Xu Z, et al
    Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
    Br J Haematol. 2021;192:1006-1010.
    >> Share

  473. LUNDIN-STROM KB, Biloglav A, Lazarevic V, Behrendtz M, et al
    Parental origin of monosomy 7 in acute leukaemia.
    Br J Haematol. 2021;192:e132-e135.
    >> Share

  474. KAYSER S, Hills RK, Langova R, Kramer M, et al
    Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
    Br J Haematol. 2021;192:832-842.
    >> Share

    February 2021
  475. SMOLEJ L, Brychtova Y, Cmunt E, Doubek M, et al
    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL St
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17373.
    >> Share

  476. WOUTERS Y, Nevejan L, Louwagie A, Devos H, et al
    Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
    Br J Haematol. 2021;192:e112-e115.
    >> Share

  477. WANG J
    Leukaemia blues - an unusual presentation of leukaemia cutis.
    Br J Haematol. 2021;192:676.
    >> Share

  478. GORDON MJ, Huang J, Chan RJ, Bhargava P, et al
    Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Br J Haematol. 2021;192:720-728.
    >> Share

  479. EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
    Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
    Br J Haematol. 2021;192:e81-e84.
    >> Share

  480. HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
    A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Br J Haematol. 2021;192:e77-e81.
    >> Share

  481. ALI AM, Cooper J, Walker A, Jones D, et al
    Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
    Br J Haematol. 2021;192:665-667.
    >> Share

  482. BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
    Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
    Br J Haematol. 2021;192:484-493.
    >> Share

  483. FLOETH M, Elges S, Gerss J, Schwoppe C, et al
    Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2021;192:494-503.
    >> Share

  484. MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
    Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2021;192:474-483.
    >> Share

  485. DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
    Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
    Br J Haematol. 2021;192:577-588.
    >> Share

    January 2021
  486. BRECCIA M
    Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:237-238.
    >> Share

  487. ROSS DM, Hughes TP
    Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
    Br J Haematol. 2021;192:24-27.
    >> Share

  488. KARAGIANNIS P, Alsdorf W, Tallarek AC, Blohm ME, et al
    Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
    Br J Haematol. 2021;192:e60-e63.
    >> Share

  489. FOUZIA NA, Sharma V, Ganesan S, Palani HK, et al
    Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
    Br J Haematol. 2021;192:292-299.
    >> Share

  490. JIN W, Chen L, Liu Y, Chen Q, et al
    A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:e32-e36.
    >> Share

  491. OTTAVIANO G, Baird S, Bonney D, Connor P, et al
    The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
    Br J Haematol. 2021;192:e42-e44.
    >> Share

  492. CAVALLINI C, Galasso M, Pozza ED, Chignola R, et al
    Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2021;192:333-342.
    >> Share

  493. GALE RP, Saglio G
    Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?
    Br J Haematol. 2021;192:22-23.
    >> Share

  494. MATSUO H, Wakita T, Hiramatsu H, Ohmori K, et al
    Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
    Br J Haematol. 2021;192:e7-e11.
    >> Share

  495. MASON CC, Fiol CR, Baker MJ, Nadal-Melsio E, et al
    Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
    Br J Haematol. 2021;192:137-145.
    >> Share

  496. FRISANCO OLIVEIRA A, Tansini A, Toledo TR, Balceiro R, et al
    Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
    Br J Haematol. 2021;192:129-136.
    >> Share

  497. RADICH J
    Molecular testing of chronic myeloid leukaemia in low resource areas.
    Br J Haematol. 2021;192:28-32.
    >> Share

  498. DUAN W, Liu X, Jia J, Wang J, et al
    The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
    Br J Haematol. 2021;192:265-271.
    >> Share

  499. MILOJKOVIC D, Cross NCP, Ali S, Byrne J, et al
    Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
    Br J Haematol. 2021;192:62-74.
    >> Share

    December 2020
  500. NAKAHATA S, Morishita K
    Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.
    >> Share

    November 2020
  501. ZHANG X, Suo S, Wang J, Jin J, et al
    IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
    Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.
    >> Share

  502. SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
    Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
    >> Share

    October 2020
  503. HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
    Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.
    >> Share

    April 2020
  504. AOKI T, Takahashi H, Tanaka S, Shiba N, et al
    Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2020 Apr 26. doi: 10.1111/bjh.16656.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016